


IN THE CLAIMS

Please cancel claims 1-20 without prejudice or disclaimer.

Please add the following new claims 21-34.

For the Examiner's convenience, all pending claims are listed below. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

21. (New) An isolated polypeptide selected from the group consisting of:

- 
- a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-65, 5
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-65,
 - a) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-65, and
 - b) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-65.

22. (New) An isolated polynucleotide encoding a polypeptide of claim 21.

23. (New) A recombinant polynucleotide comprising a promoter sequence operably linked to the polynucleotide of claim 22.

24. (New) A cell transformed with the recombinant polynucleotide of claim 23.

25. (New) A transgenic organism comprising the recombinant polynucleotide of claim 23

26. (New) A method of producing a polypeptide of claim 21, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 21, and
 - b) recovering the polypeptide so expressed.
27. (New) An isolated antibody which specifically binds to a polypeptide of claim 21.
28. (New) An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:66-69 and SEQ ID NO:71-130,
 - b) a polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:66-69 and SEQ ID NO:71-130,
 - c) a polynucleotide complementary to a polynucleotide of a),
 - d) a polynucleotide complementary to a polynucleotide of b) and
 - e) an RNA equivalent of a)-d).
29. (New) An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO:70,
 - b) a polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence of SEQ ID NO:70,
 - c) a polynucleotide complementary to the polynucleotide of a),
 - d) a polynucleotide complementary to a polynucleotide of b) and
 - e) an RNA equivalent of a) -d).

30. (New) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 29, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

31. (New) A method of claim 30, wherein the probe comprises at least 60 contiguous nucleotides.

32. (New) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 29, the method comprising:

- a) amplifying said target polynucleotide using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide and optionally, if present, the amount thereof.

33. (New) A composition comprising the polypeptide of claim 21 and a pharmaceutically acceptable excipient.

34. (New) A method for treating a disease or condition associated with decreased expression of functional HTRM, comprising administering to a patient in need of such treatment the composition of claim 33.